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Abstract
The mechanisms that regulate the differentiation program of multipotential stem cells remain poorly
understood. In order to define the cues that delineate endothelial commitment from precursors, we
screened for candidate regulatory genes in differentiating mouse embryoid bodies. We found that
the PR/SET domain protein, PRDM6, is enriched in flk1(+) hematovascular precursor cells using a
microarray-based approach. As determined by 5′ RACE, full length PRDM6 protein contains a PR
domain and four Krüpple-like zinc fingers. In situ hybridization in mouse embryos demonstrates
staining of the primitive streak, allantois, heart, outflow tract, para-aortic splanchnopleura (P-Sp)/
aorto-gonadal-mesonephric (AGM) region and yolk sac, all sites known to be enriched in vascular
precursor cells. PRDM6 is also detected in embryonic and adult-derived endothelial cell lines.
PRDM6 is co-localized with histone H4 and methylates H4-K20 (but not H3) in vitro and in vivo,
which is consistent with the known participation of PR domains in histone methyltransferase activity.
Overexpression of PRDM6 in mouse embryonic endothelial cells induces apoptosis by activating
caspase-3 and inducing G1 arrest. PRDM6 inhibits cell proliferation as determined by BrdU
incorporation in endothelial cells, but not in rat aortic smooth muscle cells. Overexpression of
PRDM6 also results in reduced tube formation in cultured endothelial cells grown in Matrigel. Taken
together, our data indicate that PRDM6 is expressed by vascular precursors, has differential effects
in endothelial cells and smooth muscle cells, and may play a role in vascular precursor differentiation
and survival by modulating local chromatin-remodeling activity within hematovascular
subpopulations during development.
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The early development of endothelial and hematopoietic lineages is closely related
spatiotemporally in the vertebrate embryo and may involve a common precursor, the
hemangioblast. Persistent expression of flk1 in these cells is associated with differentiation
along the endothelial cell lineage, whereas loss of flk1 expression characterizes differentiating
progeny [1]. Targeted disruption of the flk1 gene in mice leads to absence of both endothelial
and hematopoietic development and death in utero at E8.0-E9.0, indicating a requirement for
flk1 in the earliest stages of hematovascular development [2]. Embryonic stem (ES) cell-
derived embryoid bodies have been used to track hemangioblast induction and specification
to the endothelial or hematopoietic lineage, and flk1 (+) cells define a major population of
hemangioblasts [3,4]. Vascular cells derived from flk1 (+) cells can organize into vessel-like
structures consisting of endothelial tubes supported by mural cells in three-dimensional culture,
demonstrating that flk1 is not only one of most specific markers highlighting the earliest stage
of hematopoietic and vascular lineages, but that flk1+ precursors may also contribute to mural
lineages and cardiomyocytes, acting as ‘vascular progenitor cells’ [5,6].
We have sought to identify molecular determinants of vascular formation using an in vitro ES
cell differentiation system by analyzing global expression patterns in the developing
vasculature. This approach, for example, has revealed the importance of Wnt activation during
differentiation of flk1+ precursors [7]. In the course of this analysis, we also noted the
preferential expression of PRDM6, a PR/SET domain containing protein, in flk1+ cells at
selected time points during differentiation. The PR domain, first noted as the PRDI-BF1-
RIZ1 homologous region, characterizes a subfamily of Krüppel-like zinc finger genes that
function in cell-fate decision and malignant transformation [8–13]. A splice variant of PRDM6
was recently identified in a search for mRNAs highly expressed in aortic smooth muscle
[14]. It was characterized as an SMC-restricted epigenetic regulator, and therefore named
PRISM/PRDM6 (PR domain in smooth muscle). Here we report the cloning and
characterization of multiple full-length isoforms of PRDM6, characterize its expression in sites
known to be enriched in vascular precursor cells during embryogenesis, and demonstrate its
gene functions in endothelial cells, including methylation of histone H4 (but not H3), induction
of apoptosis and cell-cycle arrest at G1, and reducing tube formation in endothelial cells. These
results suggest roles for PRDM6 in early stages of vascular precursor differentiation and




Mouse myocardial endothelial cells (MEC), Py-4-1 mouse hemangioma endothelial cells,
C166 mouse embryonic yolk sac endothelial cells, mouse aortic smooth muscle cells (MASM)
and rat smooth muscle cells (RASM) were grown in DMEM with 10% FBS [15]. Neonatal rat
cardiomyocytes (RCM) were isolated as previously described [16].
5′ RACE
The 5′ region of mouse PRDM6 cDNA was cloned by rapid amplification of cDNA ends using
total RNA from sorted flk1 (+) cell populations of differentiated ES cells. The primer used for
5′ RACE was: 5′—CTTTTGTTGAAGGGCTGCAGGGCAT—3′.
Construction of PRDM6 expression plasmids
5′ ready cDNA was used as a template for amplification of full-length PRDM6 cDNA.
Sequence containing the putative initiation codon from 5′ RACE product was used as the 5′
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primer and the sequence containing the putative stop codon was used as the 3′ primer. The
PCR products were cloned and sequenced. Four novel isoforms of PRDM6 were generated.
For mammalian expression, the coding sequence were cloned into pCMVtag2B to create
pPRDM6/4#, pPRDM6/3#, pPRDM6/33# and pPRDM6/36#, with an amino-terminal FLAG
tag for immunodetection.
Northern blot analysis, in situ hybridization and RT-PCR
Northern blot analysis was conducted as described with a DNA probe from 210 bp to 594 bp
of PRDM6/4# (a fragment common to all isoforms) [17]. For in situ hybridization, embryos
were collected at different times from pregnant CD-1 mice. After fixation in 4%
paraformaldehyde, embryos were stained with a digoxigenin-labeled antisense RNA probe
(from 165 bp to 1132 bp) or a respective sense control. Digoxigenin was detected with an
alkaline phosphatase-conjugated antibody, and the reaction was developed by adding nitroblue
tetrazolium. The oligonucleotides used for RT-PCR to detect specific gene expression were:
mouse PRDM6 (sense: 5′—CGTAATGGAAGCCATGTGCCGACAG—3′, antisense: 5′—




Immunostaining of cultured cells with anti-FLAG, anti-Histone H4 antibody (Abcam) and
DAPI was performed as previous described [15]. Confocal immunostaining images were
collected using a Leica SP2-AOBS confocal microscope and analyzed with Leica Confocal
Software.
Histone methyltransferase (HMTase) assay
HMTase assays were performed essentially as described [18]. Briefly, similar amounts of
proteins were immunoprecipitated from transfected HEK293 cells with Anti-FLAG-M2
affinity gel, and then were incubated with core histones (4 μg) in 32.5 μl reactions containing
20 mM Tris-HCl (pH 8.0), 4 mM EDTA, 1 mM PMSF, 0.5 mM DTT, and 1 μl 3H-SAM (15
Ci/mM; NEN Life Science Products) for 1 hr at 30°C. Proteins were separated in an 18% SDS-
PAGE. For methylation site determination, HeLa cells were used for transfection and HMT
assays were carried out with 2 mM of unlabeled SAM. Methylation sites were detected by
Western blot analysis with specific antibodies. GST-SET7 was used as a control for H3-K4
methylation. For in vivo HMTase assays, core histones were purified from transfected HeLa
cells and were then probed with specific antibodies as indicated.
Recombinant adenovirus and infection assays
PRDM6-expressing recombinant adenovirus was constructed by inserting Flag-tagged
PRDM6/4# gene into GFP-expressing AdTrack. Cells seeded at 2 × 106 cells per 10-cm plate
were incubated with adenovirus for 1 h in serum-free media. The media were then
supplemented with serum to 10% and the culture was continued for the indicated times.
Growth, cell cycle and apoptosis assays
Living cell numbers were counted by trypan blue exclusion after 24 h of infection. Infected
cells were also collected 18 h post infection and processed for DNA histogram analysis [19].
Cells were dispersed with trypsin/EDTA and were pooled with cells in the culture medium
[20]. These cells were washed once with cold PBS and fixed with 80% ethanol. Cells were
then washed once in PBS/0.2% BSA and incubated in propidium iodide/RNase A for 30 min.
The stained cells were analyzed using a Becton Dickinson FACScan with Cytomation Summit
software.
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BrdU cell proliferation assay
Cell proliferation assessment using BrdU incorporation was carried out using a modified
technique [21]. Briefly, cells infected for 18 h were pulse-labeled for 1 h with 10 μM BrdU.
Cells were fixed and permeabilized with 2M HCl followed by subsequent washes with 0.1 M
sodium tetraborate and PBS. BrdU incorporation was demonstrated by incubation with a PE-
conjugated anti-BrdU mAb in buffer (10 mM HEPES, 150 mM NaCl, 0.04% FBS, 0.1% NaAz,
0.5% Tween 20) for 30 min, washed twice with the same buffer and then stained with 7-AAD.
The stained cells were analyzed using a Becton Dickinson FACScan with Cytomation Summit
software. The samples were analyzed for two-parameter dot plot histogram analysis (BrdU
incorporation vs. DNA content) [22].
Tube formation assay
48-well plates were coated with growth factor-reduced Matrigel (Becton Dickinson) at 4°C
and incubated for 30 minutes at 37°C. MEC or C166 cells were infected with AdPRDM6 or
AdGFP for 9 h and then were trypsinized and seeded into Matrigel-coated wells at a density
of 5 × 104 cells. After 12 h incubation, cells were observed under bright light and fluorescence
microscope. Total tube length per field was measured and analyzed using Image J software
[23,24].
RESULTS
Preferential expression of PRDM6 gene in flk1(+) vascular precursor cells
Using an unbiased microarray assay of in vitro differentiated ES cells, we have identified genes
potentially involved in the earliest stages of endothelial cell differentiation in flk1(+)
populations [7]. Approximately 22000 mRNAs were analyzed, and we identified a sequence
for PRDM6 among the most differentially expressed genes (Figure 1A). We found PRDM6
was preferentially expressed in flk1 (+) cells at early stages of differentiation, with the highest
enrichment of 8-fold at 84 hr (Figure 1B). RT-PCR confirmed strong preferential expression
of this cDNA in flk1 (+) cells derived from embryoid bodies (Figure 1C). Remarkably, this
differential expression is lost after 8 days of differentiation, when flk1 (+) cells are primarily
mature endothelia.
Characterization of the PRDM6 gene
To characterize the potential function of PRDM6 during vascular development, we cloned the
gene through 5′ RACE using an internal primer. An initial 1.5 kb fragment of PRDM6 contains
a single open reading frame and the nucleotide sequence around the first methionine conforms
to the Kozak initiator sequence GACATG [25]. We were able to isolate the full-length mouse
PRDM6 cDNA using primer sequences covering the putative initiation codon and stop codon
to generate a 565 a.a species of PRDM6 (which we designated PRDM6/4#) in which the amino-
terminal 170 amino acids are unique, and the remainder of the protein is identical with PRISM/
PRDM6 (Figures 2A and 2B) [14]. Analysis of the predicted protein by comparison with the
SMART algorithm (http://smart.embl-heidelberg.de) indicated the presence of a PR domain
and four zinc finger motifs at the carboxyl terminus (Figure 2A). These domains are all
characteristic of PR family proteins.
The gene is located on mouse chromosome 18 and contains 8 exons spanning 110.5 kb (See
Supplemental Figure). Further screening of PCR products and sequence analysis revealed three
more isoforms of PRDM6, referred to herein as PRDM6/3#, 33#, and 36# (Figure 2C).
Sequence alignment among the isoforms and comparison with the genomic sequence revealed
that insertions near the amino terminus were generated by alternative splicing. The additional
sequences of 31 residues in both PRDM6/3# and PRDM6/33# retain the first intron that is
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spliced from PRDM6/4#. Similarly, PRDM6/36# has alternative splicing 3 base pairs upstream
of the intron1/exon2 boundary, resulting in a single amino-acid insertion compared to
PRDM6/4#. PRDM6/33# also has an internal alternative splicing event that results in the
deletion of exons 3–5 of PRDM6/4# to become a PR-minus isoform. A unique carboxyl-
terminal sequence is also found in PRDM6/36# from a single novel exon 8 that results from
alternative splicing in intron 7 of PRDM6/4#. Since exon 8 of PRDM6/36# includes an in-
frame stop codon, it encodes 48 residues of a unique carboxyl terminus lacking a fourth zinc
finger. Generation of multiple isoforms from a single gene is typical of PR domain-containing
proteins [26–28].
Expression patterns of PRDM6
The embryonic and adult tissue expression of PRDM6 in mice was determined by Northern
blot analysis. PRDM6 is detectable as early as E7.5 with expression in the allantois, yolk sac,
and placenta (Figure 3A). In adult mice, mRNA expression was highest in the spleen, lung,
ovary and bone marrow, and lower levels of expression were detected in the heart (Figure
3B). Murine PRDM6 mRNA was expressed as a major band around 4 kb in embryos and tissues,
with two shorter and one longer form of mRNA indicating alternative PRDM6 transcripts.
Analysis of cell lines by RT-PCR revealed PRDM6 mRNA in MASM, RCM, cell lines derived
from yolk sac (C166) and intraembryonic myocardial endothelial cells (MEC). The anatomical
distribution of PRDM6 mRNA during embryogenesis was mapped by in situ hybridization
with staining first detected in allantois/primitive streak regions at E7.5 (Figure 3D). Analysis
of mouse embryos at E8.5–E9.5 showed characteristic staining in the heart and P-Sp/AGM
region that hosts hematovascular progenitors (Figures 3E and 3G), and persistent staining of
the allantois. Additionally, expression in the outflow track and yolk sac vasculature was evident
at E9.5 (Figures 3H and 3I). Hybridization with sense mRNA demonstrated the specificity of
this expression pattern (Figure 3F). Taken together, these data indicate that PRDM6 is
expressed in sites enriched for vascular precursor cells in both the embryonic and the
extraembryonic compartments.
Identification of PRDM6 as an H4-k20 Specific HMTase
To examine PRDM6 function, PRDM6 isoforms were subcloned into a mammalian expression
vector and transiently transfected into HEK293 cells to generate FLAG-tagged fusion proteins
that were detectable as an appropriately sized protein by Western blot analysis (data not
shown). PRDM6/4# was located in the nucleus as determined by immunofluorescence analysis
(Figure 4A). PRDM6/33# and PRDM6/36# isoforms were also localized to the nucleus, and
PRDM6/36# was expressed in what appeared to be the nuclear envelope region (data not
shown). Confocal microscopic colocalization studies revealed the overlapping expression of
PRDM6/4# with histone H4 within the nucleus (Figure 4B). Based on the presence of the PR
domain, we hypothesized that PRDM6 might be able to transfer methyl groups onto suitable
substrate proteins. PRDM6 isoforms were immunopurified from HEK293 cell extracts and
analyzed using an in vitro histone methyltransferase assay with core histones as the substrate.
SET7, a highly active H3-K4 specific HMTase, was used as a positive control. The
immunoprecipitated PRDM6/4# protein had methyltransferase activity selective to histone H4
and not to other histones, although the activity was weak (Figure 4C, top panel). PRDM6/33#
and PRDM6/36#, to our surprise, also specifically methylated H4. PRDM6/33#, which lacks
a PR domain, showed stronger HMTase activity when equal amounts of enzymes (Figure
4C, lower panel) were applied to equal amounts of core histones (Figure 4C, middle panel).
The fact that PRDM6/33# retains histone H4 methyltransferase activity suggests that PRDM6
contains histone H4 methyltransferase activity independent of the PR domain or that PRDM6
interacts with other HMTase proteins. Because recombinant PRDM6 proteins purified from
bacteria lack HMTase activity in this assay (data not shown), it seems most likely that PRDM6
associates with another protein in mammalian cells that is required for HMTase activity. This
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would be analogous to the situation with PRDM1/PRDI-BF1/Blimp-1, another PR domain-
containing protein that also requires a co-purifying partner protein for activity [29].
To further identify the target amino acid residue of PRDM6, FLAG-tagged PRDM6/4# and
SET7 were recovered from transfected HeLa cells, and in vitro HMTase assays were carried
out. As expected, both GST-SET7 and SET7 methylated H3-K4 (data not shown), whereas
PRDM6 selectively methylated H4 at lysine20 (Figure 4D). We also examined whether
PRDM6 has methyltransferase activity towards H4-K20 in vivo. To this end, Flag-tagged
PRDM6/4# and SET7 were transfected into HeLa cells respectively. Core histones purified
from the transfected cells were analyzed by Coomassie blue staining and Western blotting
using antibodies specific for methylated H4-K20 [30]. As seen in Figure 4E, overexpression
of PRDM6 had an obvious effect on H4-K20 methylation, which indicates that PRDM6
methylates H4-K20 in vivo. Collectively, these data suggest that PRDM6 is responsible for
H4-K20 methylation in vitro and in vivo. Notably, this conclusion differs from previous
suggestions that PRISM/PRDM6 is a histone H3 methyltransferase [14].
Detection of apoptosis and cell cycle arrest caused by PRDM6 in MEC
Our attempts to knock down PRDM6 expression via siRNA technology were hampered
because of alternative splicing within the PRDM6 gene, leading to upregulation of various
alternative isoforms when specific exons were targeted. Therefore, recombinant adenovirus
AdPRDM6 was made with FLAG-PRDM6/4# and infected into MEC to determine the cellular
effects of PRDM6 in cultured endothelial cells. AdPRDM6-infected cells grew more slowly
than cells infected with control AdGFP, and cell death (as determined by Trypan blue inclusion)
became apparent 24 h post infection in 40% of cells, whereas control virus-infected cells did
not exhibit significant cell death (Figure 5A). To characterize the cell death caused by
overexpression of PRDM6, infected cells were harvested at different time points. PRDM6
protein expression was evident at 9 h post infection and activation of apoptotic marker
caspase-3 was first detected at 15 h, indicating activation of the caspase-3 terminal apoptotic
pathway in PRDM6-induced apoptosis (Figure 5B). DNA content analysis with PI staining
was performed as an independent assay for apoptosis. Decreased cell size and increased
refractory index were observed in AdPRDM6 infected cells, a feature of apoptotic cells.
Quantitation of percentages of cells within different phases of the cell cycle demonstrated a
significant increase of apoptotic cells and cell cycle arrest at G1 in PRDM6-infected endothelial
cells (Figure 5C). In contrast, AdFGP-infected cells were mostly in G1 and did not undergo
apoptosis. These experiments indicate that PRDM6 can induce G1 arrest and/or apoptosis in
MEC (Figure 5D).
Effect of PRDM6 overexpression on cell proliferation is cell-type dependent
These observations were surprising insofar as overexpression of PRISM/PRDM6 has
previously been shown to elicit a modest proliferative response in smooth muscle cells by
inhibiting genes associated with the differentiation pathway [14]. This discrepancy prompted
us to characterize PRDM6-induced cell-cycle arrest in more detail. DNA synthesis rate was
evaluated by incorporation of BrdU into DNA by flow cytometry. As shown in Figure 6A,
endothelial cells overexpressing PRDM6 had a lower ratio of BrdU incorporation (25 %)
compared with AdGFP-infected cells (40 %). To confirm that over-expression of PRDM6 has
different effects in two different cell lines, BrdU incorporation assay was conducted with
RASM with the same conditions. In contrast with endothelial cells, there was no suppression
of BrdU uptake in smooth muscle cells (Fig 6B). The BrdU incorporation results are
summarized in (Fig 6C). These results indicate that PRDM6 has differential effects on viability
and proliferation among cells within the vascular lineage. This may explain the loss of
preferential expression of PRDM6 we observed at times when endothelial cells have matured
(Figure 1C).
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Effects of PRDM6 on endothelial cell assembly in vitro
To further explore the effects of PRDM6 on endothelial function, we utilized a Matrigel-based
culture system that provides a method to evaluate key components in neovascular growth:
directional endothelial cell migration, cell-cell contact and pattern formation. The effects of
PRDM6 in this system were examined in two embryonic endothelial cell lines, MEC and C166,
using growth factor-reduced Matrigel. When infected with AdGFP, both cell lines migrated,
attached to one another and formed microvessel-like structures on reconstituted basement
membrane that resemble a remodeling capillary bed (Figures 7A and 7B). In contrast,
AdPRDM6-infected cells had markedly diminished capacity to assemble organized structures
(summarized in Figure 7C), with markedly limited numbers of cells remaining alive,
underscoring an antagonistic role of PRDM6 on events that are required for normal endothelial
cell survival and differentiation in vascular structures.
DISCUSSION
In this report we have shown that PRDM6 is preferentially expressed in fk1(+) cells in
differentiated ES cells and in the allantois, primitive streak, P-Sp/AGM regions and yolk sac
during mouse development (Figures 3), all regions known to host vascular precursors [31–
37]. In agreement with previous data, PRDM6 is expressed in adult aortic SMC and is also
detected in embryo-derived endothelial cells (Figure 3) [14]. This pattern of expression pattern
suggests a role for PRDM6 in early stages of vascular development, and provided us with an
impetus to characterize the function of this protein further.
The presence of the PR/SET domain raised the strong possibility that PRDM6 may have
HMTase activity, although this activity is not intrinsic to all PR-domain containing proteins.
For example, PRDM2/RIZ methylates histone H3 on lysine 9 through an intrinsic activity that
requires the PR domain [38]. In contrast, PRDM1/PRDI-BF1/Blimp-1, another PR domain
protein, participates in methyltransferase reactions although its HMTase activity is extrinsic,
exerting HMTase activity in transcriptional silencing only when G9a, a Histone H3-K9 and
K27 dimethyl HMTase, is recruited into a complex [29,39]. Interestingly, PRISM/PRDM6 was
also reported to associate with G9a and methylate Histone H3 [14]. In this report, we
demonstrate in contrast that immunopurified full-length PRDM6 isoforms are able to methylate
histone H4-K20 (but not other histones) in a PR domain-independent fashion (Figure 4C). It
is not clear if additional amino-terminal sequences or co-associating proteins confer this
function at the present time. Defining the functional domains or interacting partners of PRDM6
responsible for its HMTase activity will be an important area of future investigation.
All presently reported members of PR family proteins have growth repressive activity. For
example, overexpression of PRDM2/RIZ1 and PRDM5 induces G2/M cell cycle arrest and
apoptosis in cancer lines [40,41]. Blimp-1 inhibits cell differentiation and induces apoptosis
in a cell type-dependent fashion [42]. Similarly, we found that PRDM6 induces apoptosis and
cell cycle arrested at G1 in endothelial cells, but not in smooth muscle cells (Figures 5 and 6).
Based on our determination that PRDM6 is preferentially expressed in flk1(+) vascular
precursor cells and its differential effects on endothelial and smooth muscle cells, we speculate
that PRDM6 may coordinate cell fate decisions in vascular progenitor cells that favor smooth
muscle over endothelial differentiation, or may selectively ablate cells progressing down the
endothelial lineage during early stages of vascular remodeling. This is consistent with the
observation of Davis et al. that PRDM6 is expressed primarily in smooth muscle compartments
at later stages of murine development [14].
To date, the best-characterized PR protein in cell fate choice is Blimp-1. In the B lymphocyte
lineage, expression of this transcriptional repressor is restricted to mature B cell subsets, and
early B cell development is unimpaired by Blimp-1 disruption [43]. Blimp-1 represses a series
Wu et al. Page 7













of genes whose transcription factor products regulate growth control, apoptosis, antigen
receptor signaling, and lineage commitment [44,45]. It was therefore widely accepted as a
master regulator of plasma cell differentiation. Recently, two groups took different approaches
to extend the function of Blimp1 to the homeostasis and activation in T cells [12,13]. The idea
that Blimp-1 may function in early T cell maturation is suggested by the observation that
double-positive thymocytes are reduced in number and are prone to apoptosis in mice with T
cell–restricted Blimp-1 deletion [13]. It is likely that similar epigenetic mechanisms of
regulation exist within the vascular developmental program, and our data indicate that PRDM6
is a likely candidate to participate in these regulatory programs that determine vascular cell
fate.
Our data support the conclusions of Davis et al. that PRDM6 is a vascular-restricted protein
that functions as an HMTase, although it is important to reconcile key differences between
these studies [14]. The multiple sequences of PRDM6 that we identified have a long open
reading frame with conserved Kozak sequences around the initiation codon, and conform to
expressed sequence tags that are present in GenBank. The isoform PRDM6/4# is identical to
PRISM/PRDM6, except that it has an additional amino-terminal 170 residues. PRISM/PRDM6
appears to represent an isoform expressed via an alternative promoter specifically in smooth
muscle cells. Our data and those of Davis et al. support a role for PRDM6 in HMTase activity,
but our data indicate that PRDM6 methylates histone H4 at lysine 20, whereas the previous
report suggests that PRDM6 utilizes histone H3 as a substrate. A key difference between these
reports is that Davis et al. used purified histone H3 alone in their assays, whereas we use a
histone preparation that contains all nuclear histones in a natural stoichiometry. Thus, when
all histones are present, histone H4 is clearly preferred as a PRDM6 substrate and no histone
H3 methylation is detectible (even though we see histone H3 methylation by SET7 under the
conditions of our experiments). Finally, we believe that the differential effects of PRDM6 on
smooth muscle proliferation compared to the anti-proliferative and pro-apoptotic effects of
PRDM6 we observe in endothelial cells (Figures 5 and 6) most likely represent biologically
meaningful distinctions that may allow PRDM6 to determine cell fate decisions within vascular
progenitor populations, a hypothesis that is strongly supported by the patterns of expression
of PRDM6 in early and later stages of vascular development examined in our respective studies
[14].
The PRDM gene family of transcriptional factors is characterized by the presence of multiple
isoforms. Aside from the PR-plus and PR-minus variants, there are multiple other isoforms
that can be generated by alternative splicing or by alternative promoter usage. Many lines of
investigation suggest that PRDM genes seem to have a dual function that follows a similar
pattern: the PR-plus isoform behaves as tumor suppressor, while the PR-minus isoform
functions as an oncogene since the PR-plus product is found disrupted or underexpressed
whereas the PR-minus product is present or overexpressed in many types of cancer cells [20–
28]. Here we reported the discovery of four more isoforms of PRDM6 in addition to the reported
PRISM/PRDM6 [14]. Isoforms PRDM6/4# and PRISM/PRDM6 apparently have different
functions in the differentiation and proliferation of endothelial cells and smooth muscle cells
respectively. It will be interesting to analyze the expression of gene variants in both cell types
and in in vitro ES differentiation system. The proper balance of the variants, a result of either
genetic or epigenetic events, might be critical in maintaining the chromatin-mediated control
of gene expression and normal cell homeostasis during embryonic development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PRDM6 gene expression is enriched in flk1(+) vascular precursors
A. A hierarchical cluster was assembled from a previous microarray analysis [7] containing
PRDM6 and co-expressed genes in flk1(+) and flk1(−) cells during ES cell differentiation. The
color scale ranges from green for log ratio −2 to red for log ration +2, as indicated. B. Relative
enrichment of PRDM6 mRNA in the flk1(+) cell population by microarray assay. C.
Differential expression of PRDM6 mRNA was confirmed by RT-PCR.
Wu et al. Page 12













Figure 2. PRDM6 structure
A. Schematic map of mouse PRDM6/4# (isoform 4 of PRDM6) protein structure. The PR
domain is shown in brown and the Krüpple-like zinc fingers (ZN) are shown in blue. The amino
acid positions of the initiation codon and motifs are indicated. B. Deduced amino acid sequence
of PRDM6/4#. C. Schematics of different PRDM6 isoforms cloned. Compared to PRDM6/4#,
isoforms PRDM6/3#, PRDM6/33# and PRDM6/36# have additions of 31 a.a, 31 a.a and 1 a.a
inserted after residue 28. PRDM6/33# also has a 187 a.a deletion including the entire PR
domain. PRDM6/36# has different splicing between the third and forth ZN, resulting in loss
of the fourth ZN, producing an alternative 48 residues at the carboxyl terminus. Insertion (Δ),
deletion (⋁) or alternative splicing (---) are marked compared to PRDM6/4#.
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Figure 3. Tissue and cell distribution of PRDM6
A and B Total RNA from mouse embryos (A) and mouse adult tissues (B) were isolated.
Northern blots were hybridized with a PRDM6 probe. One major (marked as arrow) and three
minor (marked as arrowhead) types of PRDM6 were detected. C. Specific primers for PRDM6
were used to detect gene expression in different cell lines by RT-PCR. PRDM6 was detected
in mouse endothelial cells MEC and C166, MASM and RCM. D–I. PRDM6 expression in
early embryos. D. Specific staining with antisense probe was detected in the allantois and
primitive streak regions. E, G. Detection of PRDM6 mRNA in the heart, outflow tract, and P-
Sp/AGM region. H. Enlarged view of outflow tract from G. I. PRDM6 mRNA was detected
in the vessels of E9.5 yolk sac. F. Control staining using sense probe. Abbreviations: all,
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allantois; ps, primitive streak; ht, heart; ot, outflow tract; P-Sp/AGM, para-aortic
splanchnopleura/aorta-gonad-mesonephros; ys, yolk sac.
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Figure 4. Nuclear localization and HMTase activity of PRDM6
A. FLAG-tagged plasmid pPRDM6/4# was transfected into HEK293 cells. After fixation, cells
were immunostained with anti-FLAG antibody and DAPI and visualized by fluorescence
microscopy. Magnifications 20X. B. PRDM6/4# co-localized with histone H4 in nucleus by
confocal immunostaining assay. C. PRDM6/4# was immunoprecipitated by anti-FLAG
antibody before enzymatic methyltransferase activity was measured. The amount of purified
protein used in the assay was normalized by immunoblotting with anti-FLAG (lower panel).
SET7 is used as a positive control. Samples derived from empty-vector transfected cells were
used to control for nonspecific background. Methylated histones were visualized by SDS-
PAGE and autoradiography (upper panel). The position of each histone substrate and the
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amounts present in each assay is demonstrated by Coomassie blue staining of gel (middle
panel). These results are representative of three independent experiments. D. HeLa cells were
transfected with the indicated plasmids. HMTase assays were performed as for C except
unlabeled SAM was used. Reaction mixtures were resolved by SDS-PAGE and methylation
sites were determined by Western blotting analysis with specific antibodies. GST-SET7 was
used as control for H3-K4 methylation. E. Core histones were extracted from transfected HeLa
cells as indicated and electrophoresed by SDS-PAGE. In vivo methylation sites were detected
by Western blotting analysis with specific antibodies.
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Figure 5. PRDM6-induced apoptosis and cell cycle arrest in MEC
A. Cell death was observed in MEC infected with AdPRDM6. Living cells were counted by
trypan blue exclusion at 24 h post-infection. Shown is a representative of three independent
experiments. Cell counts were expressed as a percentage of control cells with AdGFP infection.
B. Western blot analysis of cell extracts from AdPRDM6-infected MEC. MEC cells were
infected with AdPRDM6 or AdGFP. Cell lysates were harvested at various times post infection
as indicated on top of each lane and were analyzed by immunoblot analysis using FLAG
antibody (upper panel), caspase-3 antibody (middle panel) and cleaved caspase-3 antibody
(lower panel). C. Cell cycle profile of MEC infected by AdPRDM6. Infected cells were
analyzed by propidium iodide staining followed by flow cytometry. The percentages of cells
that fall within the indicated gate are noted. Values of less than 2% represent background
Wu et al. Page 18













staining. The Y-axis represents the relative cell number. The X-axis represents DNA content.
A representative of four independent experiments is shown D. The results in C are expressed
as the mean ± SD of three independent experiments. *, P<0.01.
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Figure 6. PRDM6 affects DNA synthesis in cell type-dependant manner
MEC (A) and RASM (B) were infected for 18 h and then were incubated with BrdU. BrdU
incorporation was measured by flow cytometry after staining with anti-Brdu antibody and 7-
AAD. The percentages of cells that fall within the indicated gate are noted. The Y-axis
represents fluorescence intensity of BrdU-PE. The X-axis represents DNA content. C. Shown
is representative experiment of three independent experiments in A and B.
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Figure 7. Effects of PRDM6 on endothelial cell assembly in Matrigel
MEC and C166 were infected with AdPRDM6 or AdGFP for 9 hr. Then equal numbers of
cells were seeded onto growth factor-reduced Matrigel for 12 hr. Markedly decreased tube
formation was observed in the AdPRDM6-infected cells. Representative micrographs show
the capillary-like structures formed by MEC (A) and C166 (B). Bar, 100 μm. C. The results in
A and B are expressed as the mean ± SD of three independent experiments. Tube length obtained
from AdGFP-infected MEC was set to 100.*, P<0.01.
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